2013 Publications

2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | < 1999

  • Croxen M.A., Law R.J., Scholz R., Keeney K.M., Wlodarska M., Finlay BB. (Oct) 2013. Recent Advances in Understanding Enteric Pathogenic Escherichia coli. Clin Microbiol Rev. 2013 Oct;26(4):822-880.
  • Amaral J.J., Antunes L.C., de Macedo C.S., Mattos K.A., Han J., Pan J., Candéa A.L., Henriques M.d., Ribeiro-Alves M., Borchers C.H., Sarno E.N., Bozza P.T., Finlay BB., Pessolani M.C. (Aug) 2013. Metabonomics reveals drastic changes in anti-inflammatory/pro-resolving polyunsaturated Fatty acids-derived lipid mediators in leprosy disease. PLoS Negl Trop Dis. 2013 Aug 15;7(8):e2381.
  • Marchiando A.M., Ramanan D., Ding Y., Gomez L.E., Hubbard-Lucey V.M., Maurer K., Wang C., Ziel J.W., van Rooijec N., Nuñez G., Finlay BB., Mysorekar I.U., Cadwell K. (Aug) 2013. A Deficiency in the Autophagy Gene Atg16L1 Enhances Resistance to Enteric Bacterial Infection. Cell Host Microbe. 2013 Aug 14;14(2):216-24.
  • Bhavsar A.P., Brown N.F., Stoepel J., Wiermer M., Martin D.D., Hsu K.J., Imami K., Ross C.J., Hayden M.R., Foster L.J., Li X., Hieter P., Finlay BB. (Jul) 2013. The Salmonella Type III Effector SspH2 Specifically Exploits the NLR Co-Chaperone Activity of SGT1 to Subvert Immunity. PLoS Pathog. 2013 Jul;9(7):e1003518.
  • Buckner M.M., Antunes L.C., Gill N., Russell S.L., Shames S.R., Finlay BB. (Jul) 2013. 15-Deoxy-Δ(12.14)-Prostaglandin J2 Inhibits Macrophage Colonization by Salmonella enterica Serovar Typhimurium. PLoS One. 2013 Jul 26;8(7):e69759.
  • Donnenberg M.S., Finlay BB. (Jul) 2013. Combating enteropathogenic Escherichia coli (EPEC) infections: the way forward. Trends Microbiol. 2013 Jul;21(7):317-9.
  • Brown E.M. Sadarangani M., Finlay BB. (Jul) 2013. The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol. 2013 Jul:14(7).
  • Sal-Man N., Setiaputra D. Scholz R., Deng W., Yu A.C., Strynadka N.C., Finlay BB. (Mar) 2013. EscE and EscG are co-chaperones for the type III needle protein EscF of enteropathogenic E. coli. J Bacteriol. 2013 Jun;195(11):2481-9.
  • Imami K., Bhavsar A.P., Yu H., Brown N.F., Rogers L.D., Finlay BB., Foster L.J. (Feb) 2013. Global impact of Salmonella pathogenicity island 2-secreted effectors on the host phosphoproteome. Mol Cell Proteomics. 2013 Jun;12(6):1632-43.
  • Law R.J., Gur-Arie L., Rosenshine I., Finlay BB. (Mar) 2013. In vitro and in vivo model systems for studying enteropathogenic Escherichia coli infections. Cold Spring Harb Perspect Med. 2013 Mar 1;3(3):a009977.
  • Olsen R.L., Echtenkamp F., Cheranova D. Deng W., Finlay BB., Hardwidge P.R. (Apr) 2013. The enterojemorrhagic Escherichia coli effector protein NleF binds mammaliam Tmp21. Vet Microbiol. 2013 May 31;164(1-2):164-70.
  • Keeney K.M., Finlay BB. (Jan) 2013. Microbiology: EHEC downregulates virulence in response to intestinal fucose. Curr. Biol. 2013 Feb 4;23(3): R108-10.